Volume 19, Number 8—August 2013
Research
Accuracy of Diagnostic Methods and Surveillance Sensitivity for Human Enterovirus, South Korea, 1999–2011
Table 1
Year | No. samples | No. (%) positive | Average % positive |
---|---|---|---|
Phase I† | 20.5 | ||
1999 | 372 | 133 (35.8) | NA |
2000 | 261 | 30 (11.5) | NA |
2001 | 676 | 26 (3.80) | NA |
2002 | 1,272 | 361 (28.4) | NA |
2003 | 264 | 66 (25.0) | NA |
2004 | 314 | 33 (10.5) | NA |
Phase II‡ | 26.4 | ||
2005 | 890 | 382 (42.9) | NA |
2006 | 1,059 | 238 (22.5) | NA |
2007 | 1,131 | 193 (17.1) | NA |
Phase III§ | 39.2 | ||
2008 | 2,332 | 1,264 (54.2) | NA |
2009 | 2,766 | 869 (31.4) | NA |
2010 | 1,477 | 566 (38.3) | NA |
2011 | 1,843 | 601 (32.6) | NA |
Total | 14,657 | 4,762 (32.5) | NA |
*EV, enterovirus; NA, not applicable.
†During phase I, human EV was detected and serotyped by using cell culture.
‡During phase II, human EV was detected by reverse transcription PCR (RT-PCR) and genotyped by sequencing of virus capsid protein (VP) 1 region.
§During phase III, human EV was detected by real-time RT-PCR and genotyped by sequencing of the VP1 region.
Page created: July 19, 2013
Page updated: July 19, 2013
Page reviewed: July 19, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.